---
title: "Origin Agritech targets cash flow breakeven by 2026 with 25% revenue growth in 2024"
date: "2025-02-11 21:44:04"
summary: "Earnings Call Insights: Origin Agritech Limited (NASDAQ:SEED) Q4 2024 Management View CEO Weibin Yan highlighted a 24.6% revenue growth to $16.2 million for fiscal year 2024, driven by higher corn seed sales and an improving market. He emphasized the receipt of a GMO safety certificate for the BBL2-2 transgenic maize..."
categories:
  - "seekalpha"
lang:
  - "en"
translations:
  - "en"
tags:
  - "seekalpha"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

Earnings Call Insights: Origin Agritech Limited (NASDAQ:[SEED](https://seekingalpha.com/symbol/SEED "Origin Agritech Limited")) Q4 2024

### Management View

* CEO Weibin Yan highlighted a 24.6% revenue growth to $16.2 million for fiscal year 2024, driven by higher corn seed sales and an improving market. He emphasized the receipt of a GMO safety certificate for the BBL2-2 transgenic maize and breakthroughs in gene editing technology, enabling faster and more cost-effective trait improvements.
* CEO Yan shared the company's three-phase strategy aiming for cash flow breakeven by 2026, positioning as one of China's six leading corn companies by 2027, and achieving top-five status with 20% of revenue from overseas markets by 2032.
* Origin Agritech launched the Origin Marker Biological Breeding Service Consortium in October 2024 to collaborate with thousands of breeding companies across China, creating new revenue streams through biotechnology services.
* CFO Patrick Cheng reported that the company increased R&D investment to $1.5 million while achieving a net income of $2.7 million from continuing operations. He acknowledged the decline from the prior year due to one-time gains in fiscal 2023.
* Cheng emphasized steps to achieve profitability, including enhanced cost controls, operational efficiencies at the Xinjiang facility, and revenue growth from new seed varieties launching in 2025.

### Outlook

* Management outlined a detailed plan to achieve cash flow breakeven from operations during the 2024-2026 period as part of its Phase 1 strategy.
* Eight new seed varieties are set to launch in 2025, targeting regional adaptations and market needs, which are expected to contribute positively to revenue growth and profitability.
* CEO Yan reaffirmed the long-term vision to become a leading global biotech seed company with diversified revenue streams combining seed sales and high-margin biotechnology services by 2030-2032.

### Financial Results

* Fiscal year 2024 revenue increased to $16.2 million, up from $13 million in fiscal 2023, driven by higher corn seed sales volume.
* General and administrative expenses rose to $5.1 million due to investments in talent, systems, and professional services to support growth initiatives, while R&D expenses increased to $1.5 million, reflecting the company's focus on advancing biotechnology platforms.
* The company reported a net income attributable to Origin of $3 million, down from $7.7 million in fiscal 2023 due to the absence of prior year one-time gains.
* Cash and cash equivalents declined to $1.2 million, reflecting increased working capital investment and operating cash flow usage of $2.1 million.

### Q&A

* Analyst question on gross margin decline: CEO Yan explained that the lower margins reflect competitive industry dynamics and strategic investments. He highlighted margin improvement initiatives, including premium pricing for GMO corn varieties, cost efficiencies from new technologies, and revenue diversification through licensing and services.
* Analyst question on meeting revenue forecasts from June 2024: Yan stated that the company has surpassed prior guidance with a new eight-year roadmap focusing on sustainable growth and cash flow breakeven by 2026.
* Analyst question on transitioning fiscal year to calendar year: CFO Cheng acknowledged the potential benefits for aligning reporting with agricultural seasons and stated that the company is evaluating this change.
* Analyst question on scaling NEC production: Yan noted the decision to suspend NEC operations in favor of focusing on biotechnology commercialization and seed sales expansion, citing potential for higher value creation.
* Analyst question on gene editing commercialization: Yan highlighted the significant cost and time advantages of the new system, enabling faster development of drought-resistant and high-performing seed varieties.

### Sentiment Analysis

* Analysts expressed cautious optimism but raised concerns about historical margin trends, NEC business suspension, and fiscal year alignment. The tone during the Q&A was neutral to slightly skeptical, focusing on execution risks and growth targets.
* Management maintained a confident and forward-looking tone, emphasizing strategic milestones and operational improvements. CEO Yan frequently used phrases such as "confident we can achieve this goal" and "clear strategic roadmap" to project certainty.
* Compared to prepared remarks, management's responses during the Q&A reflected a more detailed and explanatory tone, addressing specific concerns raised by analysts.

### Quarter-over-Quarter Comparison

* No comparison to the previous quarter due to unavailability of prior quarter transcript.
* Management tone this quarter was optimistic, focusing on strategic milestones and long-term growth, with significant emphasis on new product launches and commercialization of gene editing technologies.
* Analysts' tone remained focused on execution challenges and the sustainability of the company's ambitious growth strategies.

### Risks and Concerns

* Management noted competitive pressures in the Chinese seed industry impacting margins, but emphasized plans to address this through premium pricing and cost efficiencies.
* Analysts raised concerns about cash flow pressures, given the decline in cash reserves and increased operating cash flow usage.
* The decision to suspend NEC business operations was highlighted as a potential risk, though leadership emphasized its strategic rationale.

### Final Takeaway

Origin Agritech's Q4 2024 earnings call showcased significant progress in revenue growth and strategic realignment under new leadership. The company's focus on advancing biotechnology capabilities, including GMO and gene editing technologies, positions it for long-term growth. However, increased operating expenses and cash flow pressures highlight the challenges of scaling its ambitious strategy. The planned launch of eight new seed varieties in 2025 and a clear timeline for achieving cash flow breakeven by 2026 are key milestones for investors to monitor moving forward.

[Read the full Earnings Call Transcript](https://seekingalpha.com/symbol/SEED/earnings/transcripts)

[seekalpha](https://seekingalpha.com/news/4406334-origin-agritech-targets-cash-flow-breakeven-by-2026-with-25-percent-revenue-growth-in-2024)
